**LORVAS SR**

**For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only**

Abbreviated Prescribing information for **LORVAS SR** [Indapamide 1.5mg prolonged release film coated Tablets] [Please refer the complete prescribing information available at www.torrentpharma.com]

**PHARMACOLOGICAL PROPERTIES**: Indapamide exerts its action in the control of hypertension is not completely elucidated: both renal and extra renal actions may be involved. The extra renal actions involve improvement in arterial compliance and a reduction in arteriolar and total peripheral resistance through a reduction in the contractility of vascular smooth muscle due to a modification of transmembrane ion exchanges, essentially calcium, vasodilatation due to stimulation of the synthesis of prostaglandin $PGE_2$ and the vasodilator and platelet antiaggregant prostacyclin $PGI_2$, potentiation of the vasodilator action of bradykinin.

**INDICATION**: Indicated in the management of mild to moderate essential hypertension.

**DOSAGE AND ADMINISTRATION**: One sustained release tablet daily, preferably in the morning. The tablet should be swallowed whole and must not be chewed or crushed. In more severe cases, Lorvas SR can be combined with other categories of anti-hypertensive agents like beta-blockers, methyldopa, clonidine, prazosin and ACE inhibitors.

**CONTRAINDICATION:** Contraindicated in patients with Hypersensitivity to indapamide, to other sulfonamides or to any of the excipients, severe renal failure, hepatic encephalopathy or severe impairment of liver function and hypokalaemia.

**WARNINGS & PRECAUTIONS**: Use cautiously or stop the indapamide in patient with impaired liver function, photosensitivity reactions, allergic to excipients, water and electrolyte imbalance, long QT interval, hypokalaemia, bradycardia, severe arrhythmias, fatal torsades de pointes, hypercalcaemia, hyperuricaemic patients and in athletes.

**DRUG INTERACTIONS**: Lithium, class Ia antiarrhythmics (quinidine, hydroquinidine, disopyramide), class III antiarrhythmics (amiodarone, sotalol, dofetilide, ibutilide); chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine, amisulpride, sulpiride, sultopride, tiapride, droperidol, haloperidol, bepridil, cisapride, diphemanil, erythromycin IV, halofantrine, mizolastine, pentamidine, sparfloxacin, moxifloxacin, vincamine IV, NSAIDs, ACE inhibitors, amphotericin B (IV), gluco- and mineralocorticoids (systemic route), tetracosactide, stimulant laxatives, baclofen, digitalis preparations, potassium-sparing diuretics, metformin, iodinated contrast media, imipramine-like antidepressants, neuroleptics, calcium salts, ciclosporin, tacrolimus and corticosteroids and tetracosactide (systemic route).

**ADVERSE REACTIONS**: Nausea, constipation, dry mouth, gastric irritation, maculopapular rashes, purpura, hives, pruritus, erythema multiforme, epidermal necrolysis, vasculitis, cough, rhinitis, pharyngitis, sinusitis, conjunctivitis, vomiting, abnormal hepatic function, vertigo, fatigue, headache, paraesthesia, lightheadedness, drowsiness, renal failure, increased serum urea nitrogen, or creatinine, angioneurotic oedema and/or urticaria, toxic epidermic necrolysis, steven johnson syndrome and bullous eruption.

**MARKETED BY:**

TORRENT PHARMACEUTICALS LTD.
Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

**IN/ LORVAS SR 1.5mg/Aug-2015/01/ABPI**

(Additional information is available on request)